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A B S T R A C T
Effective primary and secondary cancer prevention programmes are key to improve public health. Cervical cancer is
preventable if high quality screening programmes, diagnosis and treatment are offered to female populations at high
coverage. Nevertheless, it continues to be a public health problem, and screening programmes need improvements. Hu-
man papillomavirus (HPV) has been firmely established as the necessary cause of virtually all cervical cancer cases. To
date we count two clinically validated and approved HPV technologies, available to prevent cervical cancer, and other
diseases caused by these carcinogenic viruses: Prophylactic vaccines for primary prevention, and HPV DNA tests for sec-
ondary prevention, to detect life threatening infections by carcinogenic HPV types, allowing timely diagnosis and clinical
management of precancerous lesions. The new technologies will help improve the health of the public if made widely ac-
cessible. Similar to vaccination programmes, systematic and well organized cervical screening programmes, with high
quality validated HPV tests, can save more lives than ever and improve women’s health, in an effective manner.
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Introduction
Public health is the approach to medicine that is con-
cerned with the health of the community as a whole: pub-
lic health is community health. In this context, the mis-
sion of public health professionals is assuring conditions
in which people can be healthy. This can be achieved
through three key public health functions: 1) systematic
assessment and accurate monitoring of the health of
communities and populations at risk, to identify health
problems and their causes; 2) assuring access to appro-
priate and effective interventions, including health care
and disease prevention services, and evaluation of the
cost-effectiveness of such services; and 3) formulation of
public policies designed to solve identified global health
problems in a sustainable manner. These functions can
include the provision of personal health care (services at
the clinic level, district or referral hospital) or be popula-
tion-based such as immunization or screening program-
mes, and may also include legislation (guidelines, man-
datory interventions) and economic incentives such as
subsidies. Public health professionals are concerned with
planning and implementation of activities that fulfil one
of the three functions, leading to measurable outcomes
and improvements in the health of the public, within rea-
sonable time frame. Primary and secondary prevention
programmes have a synergistic effect in improving health.
Cervical cancer is the second most common cancer in
women worldwide with about half million new cases ev-
ery year1. Cervical cancer is preventable and readily
treatable, still it kills one of two women diagnosed with
cancer, and over 250 thousand women die annually. World-
wide, survival rates vary between regions with good
prognosis in some regions, e.g. 73% in the United States2,
and 63% showed in European registries3, where high
quality screening programmes have been implemented
in large scale.
The Human papillomavirus in the Root
of New Technologies for Cancer Prevention
The notion that papillomavirus infection underlies
the development of cancer of the cervix in women was
55
* Note: The author is an employee of Digene Switzerland. The author alone is responsible for the views expressed in this publication, and they do not
necessarily represent any corporate views, decisions or positions.









 $  
first described in 1976 by zur Hausen4. Since then, on the
basis of a variety of scientific assessements, Human pa-
pillomaviruses (HPVs) have been firmely established as
the major cause of virtually all cancers of the uterine
cervix5. This breakthrough in knowedge of cancer etiol-
ogy led to the development of innovative technologies,
that can be used as tools to improve health care and
strategies to accelerate cervical cancer prevention. For
instance, screening to identify precancerous disease sta-
tes, that can be successfully removed without sequelae,
can save lives. Cervical screening programmes have been
recommended to targeting women after the age of 25 in
some countries, although the target age and screening
intervals can be adapted to needs and resources of differ-
ent countries.
HPVs are small DNA viruses wraped by a shell or vi-
ral capsid, composed of two structural proteins expressed
late upon viral replication, known as L1 and L2. HPVs
infect the stratified squamous epithelia of skin and mu-
cous membranes, where they may cause benign lesions,
some of which have the potential to progress to invasive
cancer. Most infections are self-limited and asymptom-
atic, presumably because the host eventually mounts a
successful immune response. There are co-factors that
increase the risk for cancer development in infected sub-
jects.
While there are over 100 different types of HPVs mo-
lecularly characterized6 about 15 types have been evalu-
ated as highly carcinogenic to humans, and two types
among those have consistently been reported as most
common in cervical cancer cases, HPV types 16 and 187.
The genome of these two common types have been iso-
lated by molecular cloning in 19838 and their cloned
DNAs served as basis for producing vaccines by biotech-
nolgy methodology, as well for molecular diagnostic tests
as described bellow.
To date we count two prominent clinically validated
and approved technologies available to prevent cervical
cancer, and some other cancers caused by these carcino-
genic viruses: 1) prophylactic vaccines against HPV the
two most common carcinogenic types, and 2) molecular
HPV DNA tests to detect life threatening infections by
carcinogenic HPV types, and to allow timely diagnosis
and clinical management of precancers. On one hand,
prophylactic HPV vaccines can prevent the infections,
and therefore the associated diseases that the infectious
viruses can cause. Because they cannot influence the
course of already established infections, vaccines may be
most beneficial if administered before any infection oc-
curs. On the other hand, HPV DNA tests can identify al-
ready existing infections and prompt to early clinical
management and treatment, as appropriate, before the
early HPV associated precancerous lesions can progres-
ses to invasive cancer. These two available technologies
are schematically illustrated in Figure 1, and will be dis-
cussed bellow. Understanding the successes and limita-
tions of new technologies will help to make best use of
them for improving the health of the public in general.
HPV Vaccine Technology for Primary
Prevention
The vaccines under consideration here are recombi-
nant protein vaccines comprising L1 proteins that self-
assembly into particles similar to empty shells of the vi-
rus, and are therefore non-infectious and non-oncoge-
nic9.
The aim of vaccination against HPV is to induce im-
munity to neutralize HPV infections and later associated
diseases and cancers. Clinical data originated in several
studies in phase 1, phase 2 and phase 3 have been
published10,11. Although the primary concern is reduction
in cervical cancer cases and deaths, the impact of vacci-
nation on surrogate markers and intermediate diseases
can be assessed sooner, and may have implications for de-
sign and implementation of effective prevention pro-
grammes. This information will also be crucial for plan-
ning succesful health policy initiatives that involve both
screening and vaccination.
Vaccines that have completed controlled efficacy stud-
ies have demonstrated high levels of efficacy against
histologically characterized high grade dysplasias associ-
ated to the viral antigen types included in the vaccines,
namely cervical intraepithelial neoplasias (CIN2-3) or
worse, following administration of a three-dose regimen
among women who had no evidence of previous infection
with HPV13.
The indications for the use of HPV vaccines in the EU
are, so far, for prevention of HPV 16/18 related cervical
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Fig. 1. FDA approved technologies for use in primary and sec-
ondary cancer prevention to date. Two health technologies have
been so far approved by the US FDA and EMEA, as well as other
regulatory authorities, for prevention of neoplasis. For Primary
prevention, a prophylactic recombinant quadrivalent vaccine,
based on proteinaceous Virus Like Particles against two low risk
HPV types, 6 and 11, and two high risk HPV types 16 and 18, is
available for administration to subjects 9–26 years of age. For
secondary prevention a screening test available as two sets of re-
agents to detect 5 low risk HPV types, and 13 high risk types, for
use in laboratory diagnosis of neoplasias at risk to progress to
cancer, and recommended for routine use on women over 30 years.
HPV – Human Papillomavirus, y.o. – years old, FDA – Food and
Drug Administration, EMEA - European Agency for the Evalua-
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cancinomas, high grade cervical dysplasias CIN2 and
CIN3, high grade vulvar dysplasias, VIN2 and VIN3, as
well as prevention of HPV 6/11 related genital warts
(condyloma acuminata), and in children and adolescents
9 through 15 years of age, and women 16 through 26 years
of age14.
One pivotal vaccine trial included over 20.000 females
13–26 years old (median age of 20) enrolled in different
geographical regions. The population for the efficacy
studies included large proportion of women in Europe
(44.1%), mostly from Nordic countries, 25.3% women in
North America, 27% in Latin America and only 3.6% in
Asia (available under Food and Drug Administration
FDA and European Agency for the Evaluation of Medic-
inal Products EMEA websites15–17). It was noted that of
the females in the trial population aged 13–26 years over-
all 12% had an abnormal baseline Pap test with squa-
mous intraepithelial lesions. The majority of these were
low grade SIL and atypical squamous cells of undeter-
mined significance (ASC-US). In addition, 27% of these
subjects had been previously exposed to one or more of
the vaccine HPV types (sero+ and/or PCR+).
Different subpopulations among the randomized fe-
males enrolled in the studies were considered for analy-
ses of efficacy (Table 1)15–17. Per-Protocol Efficacy (PPE)
included subjects who received all 3 vaccinations, were
seronegative to the appropriate HPV type(s) at day 1 and
PCR-negative to the appropriate HPV type(s) day 1 through
month 7, and generally did not deviate from protocol.
Modified Intention-To-Treat (ITT-1) analysis included
subjects who received all 3 vaccinations, were serone-
gative to the appropriate HPV type(s) at day 1 and
PCR-negative to the appropriate HPV type(s) day 1 through
month 7, and included general protocol violators. Mod-
ified ITT-3 included all subjects who received at least 1
vaccination, regardless of initial serology and PCR sta-
tus.
Per Protocol HPV type-specific analyses indicated a
very high level of efficacy in naïve subjects, while the effi-
cacy for all HPV related disease on a population basis, es-
pecially if given to many females who already have an
HPV infection, appear to be lower, as summarized in Ta-
ble 1. For subjects naïve for the relevant vaccine HPV
type(s), the measured vaccine efficacy against HPV 16
and/or 18 related CIN2/3 or worse was 100%, and for all
randomized trial population, the vaccine efficacy was
about 40%, due to the fact that about a quarter of women
had evidence of previously been infected with HPV. Note-
worthy, data was analysed in a HPV type specific man-
ner. Hence, females naïve to the four vaccine HPV types
are expected to benefit most from vaccination.
Furthermore, vaccinated subjects naïve to all four
vaccine HPV types could still develop disease related to
an HPV type not included in the vaccine. In one case sce-
nario, vaccination of naive populations shows that ap-
proximately 50% reduction in cervical cancer mortality
could be achieved by vaccination in over many years12,13.
Combination of vaccination and screening strategies are
likely to offer the most effective prevention to cervical
cancer.
HPV DNA Test Technology for
Secondary Prevention
An independent study conducted by the International
Agency for Research on Cancer (IARC), and a independ-
ent Advisory Group concluded there is sufficient evidence
that screening for cervical cancer by cytological examina-
tion of Pap smear cell samples does prevent death18. The
experts, however, emphasized that in order to achieve
this goal optimally, an organized programme with quality
control of every key step of the entire process is a prereq-
uisite. Tests for the presence of viral DNA in a sample of
epithelial cells have been established as a step toward
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TABLE 1
SUMMARY OF STATISTICAL ANALYSES RESULTS FROM CLINICAL TRIALS TO MEASURE THE EFFICACY OF A QUADRIVALENT VACCINE
IN PREVENTING CIN 2–3 ASSOCIATED TO HPV INFECTIONS IN THE TRIAL POPULATION OF FEMALES AGED 15–26 YEARS OLD
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Statistical review and evaluation
GardasilTM
(Merck & Co.)**
any HPV type CIN2–3 or worse in






Clinical trials analysis to measure the efficacy of a quadrivalent vaccine in preventing CIN 2–3 associated to HPV infections in the trial
population of females aged 15–26 years old. Three trial sub-populations considered for analysis are indicated here: the HPV type spe-
cific per-protocol-efficacy analysis, the type specific modified intention to treat analysis, and the modified intention to treat analysis as
to efficacy against CIN2–3 associated to any HPV type. *Data available in the public domain, at package insert Gardasil label http://
www.fda.gov/cber/label/hpvmer060806LB.pdf, and **Interim analysis data adapted from Dr. N. Miller, available at http://www.fda.
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identifying potentially precancerous conditions. In this
context, the IARC expert Group concluded that there is
also sufficient evidence that the HPV test for women
25–65 years can reduce mortality from cervix cancer18. If
high quality screening test is provided to the public it
will likely have an immediate impact on disease burden,
in contrast to prophylactic vaccination, because it is de-
signed to identify and avert cases in the women who al-
ready have some precancer pathology and are at high
risk of progression to invasive cancer.
It is important to understand the difference between
analytical and clinical sensitivity in order to allow effec-
tive use of HPV technology for clinical diagnostics. While
analytical sensitivity relates to the amount of analyte or
genome equivalent or copy number of viral particles
present in a given sample, the clinical sensitivity relates
to the degree of agreement of a positive test result with a
positive disease status. Generally a test with high analyt-
ical sensitivity, detecting down to 10 viral copies per sam-
ple, would give positive results to all infected individuals,
irrespective if this is a transient subclinical infection or
an infection associated to neoplasia. Tests that detect
only higher levels of viral DNA, eg. more than 5000 cop-
ies per sample, give positive results that are more likely
associated to neoplasias at risk to progressing to cancer,
and so are clinically relevant19.
New diagnostic assays must be validated using data
regarding prediction of risk of cancer and CIN3 from
large representative study populations. In addition to
targeting the correct genotypes, HPV tests must have
clinically validated viral load cut points, ie. analytical
sensitivity20. Hybrid Capture 2 (HC2) is FDA-approved,
CE-marked, clinically validated, and commercial HPV
test available worldwide. The test is available with two
sets of reagents, one set to detect five low-risk types HPV,
and another reagents set to detect 13 high-risk types
HPV21. The analytical detection level of HC2 HPV has
been set at 1.0 HPV DNA pg/mL (5000 genomes/assay)
based on multiple clinical trials over a long period of time
with high grade cervical intraepithelial neoplasia (CIN
2+) as the disease endpoint22.
Primary screening with combined cytology and HPV
testing is already an accepted and approved option in
North America. The HPV HC2 test is recommended in
the United States as adjunct to cytology screening for
women over the age 30, or for triage of inconclusive cytol-
ogy results in women under 30-years old23.
In the European guidelines to be released now, evi-
dence for HPV testing is accepted for two clinical applica-
tions: triage of equivocal cytology (ASCUS), and follow-
up of treated lesions to predict failure or success of the
offered therapy24. HPV triage of LSIL is recommended
for women over 30 years of age, where the specificity of
HPV test is higher than in young women25. In Europe a
high level of confidence on primary HPV screening from
randomized trials is awaited to complement the guide-
lines. At present, there are five randomized trials under
way in Europe, to assess the effectiveness of HC2 as pri-
mary screening test for public health programmes. Simi-
larly to endpoints used in vaccine studies, screening
studies considered detect prevalent CIN2–3 in long fol-
low-up periods. In general interim studies results show-
ed that HC2 clinical performance in the field, as mea-
sured by biopsy confirmed cervical histopathology, is
consitently higher than cytology based methods (Table
2)24,26–29. A meta-analysis of the various studies con-
ducted in Europe and in North America involving over
60.000 women over 35-years old, confirmed that HC2
performance in the field to detect women with cervical
premaligant lesions, is higher than cytology. With cytol-
ogy triage, the specificity improves to the level of re-
peated conventional cytology. The studies also showed
that combining HC2 with cytology maximizes the clinical
benefits of large cervical screening programmes22.
S. R. Pagliusi: HPV Technologies Advancing Public Health, Coll. Antropol. 31 (2007) Suppl. 2: 55–60
58
TABLE 2
OVERVIEW OF RESULTS OF SOME EUROPEAN STUDIES COMPARING CYTOLOGY AND MOLECULAR METHODS DETECTION RATES
FOR HIGH GRADE CERVICAL DISEASE
Source
reference
Study site and size (N)
Any HR HPV type
CIN2+ or worse
Number of Cases
Clinical Sensitivity CIN2+ or worse
Endpoint
























513 283 96.1% 53%
*Randomized trial, **The HC2 assaw shows consistenly higher rates of disease detection in large studies, including randomized trials,
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Another advantage of HPV test is that women with a
negative result have an extremely low probability of hav-
ing a CIN in the following 10 years. The longitudinal sen-
sitivity to predict CIN3+ over a period of 10 years is 66%
for HC2 whereas only 35.4% for baseline cytology defined
as ASCUS+, while the positive predictive value of cytol-
ogy remains higher than HC230–31. Importantly, the posi-
tive predictive value of HPV test can be significantly
increased by typing for HPV 16 and 1832. These observa-
tions indicate that HPV testing is safe and could be
cost-effective allowing longer screening intervals, as op-
posed to methods such as Pap smears. In addition it may
decrease significantly psychological anxienty associated
with screening practice. Positive results for HPV 16 and
18 may warrant a shorter follow-up period.
A proposed new paradigm for cervical screening man-
agement is schematically illustrated in Figure 2. If re-
source constrains need to be respected, a HPV test would
be a possible option because it is based on the higher sen-
sitivity consistently demonstrated using HPV test, and
high sensitivity could be achieved using cytology triage,
for example34.
Conclusion
To date, two HPV technologies reviewed and ap-
proved by regulatory authorities in North America and
Europe for use in populations are at hand: HPV vaccina-
tion and HPV testing. Both technologies are derived
from the cancer causing virus, and represent effective in-
terventions to eliminate cervical cancer. Vaccines are
tools for primary prevention strategies, i.e. to prevent
the life treatening infection of establishing, and HPV
tests are tools for secondary prevention strategies, i.e.
prevent infections and neoplasias of progressing to inva-
sive cancer.
There are some limitations that need to be acknowl-
edged: vaccines to date target two out of fifteen carcino-
genic types of HPV, and will likely prevent 70% of poten-
tial cancer cases in vaccinated subjects, so screening will
need to continue in order to prevent those cases not pro-
tected by these vaccines. The vaccines are essentially
prophylactic and have no effect on the course of already
acquired infections, therefore screening needs to con-
tinue ensuring the population that previously acquired
infections will be prevented of developing to cancer. Vac-
cination may have a lag of decades between the interven-
tion and a reduction in cancer incidence at population
level. Nevertheless, these limitations could be surmoun-
ted by vaccines that would be effective against most of
the HPV carcinogenic types.
There are also limitations to HPV testing, as HC2
HPV test detects the 13 carcinogenic types identified,
and has the potential to identify 95% of cases at an early
stage to allow timely treatment. Cases caused by some
HPV types not included in the test may not be detected.
Notably, this can be overcome if the test is combined to
cytology where is has demonstrated to be able to achieve
100% sensitivity. Negative HPV test results may warrant
an assessment for appropriatness of sampling, such as
cellular DNA content.
In an ideal public health service primary and second-
ary prevention strategies implemented in parallel will
have a synergistic effect and solve the public health prob-
lem faster, than each strategy isolated. Noteworthy the
key for success in vaccination programmes lies on the
systematic and well organized approach to vaccinate the
populations at high coverage, in addition to use quality
products. Similarly, only screening programmes conduct-
ed with quality products, implemented in a systematic
and well organized manner at high coverage, while tar-
geting the female population at risk, can save lives and
improve women’s health, and will impact on the health
of their families and communities.
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POMACI U JAVNOM ZDRAVSTVU ZAHVALJUJU]I NOVIM METODAMA VEZANIM UZ HPV:
RASPRAVA O NEDAVNIM DOKAZIMA
S A @ E T A K
U~inkoviti primarni i sekundarni programi prevencije raka vrata maternice su klju~ni u pobolj{anju javnog zdrav-
stva. Rak vrata maternice je mogu}e sprije~iti ukoliko se `enama ponude kontrolirani visoko-kvalitetni programi pro-
bira, dijagnostike i lije~enja. Unato~ tomu, ovaj rak i dalje predstavlja javno-zdravstveni problem, a programe probira
treba pobolj{ati. Humani papilomavirus (HPV) se smatra neophodnim uzro~nikom gotovo svih slu~ajeva raka vrata
maternice. Danas postoje dvije klini~ki potvr|ene i odobrene metode vezane uz HPV, dostupne u prevenciji raka vrata
maternice i drugih bolesti uzrokovanih ovim karcinogenim virusima: profilakti~ka cjepiva za primarnu prevenciju te
HPV-DNK-testovi za sekundarnu prevenciju, detekciju infekcija karcinogenim tipovima HPV-a opasnih po `ivot, {to
omogu}uje pravovremenu dijagnozu te klini~ko lije~enje stadija prije raka. Nove metode }e pomo}i pomacima u javnom
zdravstvu ukoliko budu {iroko dostupne. Sli~no programima cijepljenja, sustavno i dobro organizirani programi probira
raka vrata maternice, sa visoko-kvalitetnim va`e}im HPV-testovima, mogu spasiti vi{e `ivota nego ikad te pobolj{ati
zdravlje `ena na vrlo u~inkovit na~in.
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